UBS AM
VTYX

UBS AM’s Ventyx Biosciences VTYX Stock Holding History

UBS AM’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77,234
Closed -$191K – 2561
2023
Q4 		$191K Buy
77,234
+27,900
+57% +$265K ﹤0.01% 2495
2023
Q3 		$1.71M Buy
49,334
+30,934
+168% +$1.07M ﹤0.01% 1701
2023
Q2 		$616K Hold
18,400
– – ﹤0.01% 2237
2023
Q1 		$616K Buy
18,400
+3,100
+20% +$121K ﹤0.01% 2237
2022
Q4 		$502K Buy
+15,300
New +$453K ﹤0.01% 2175

Other funds holding VTYX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

UBS AM's VTYX Position: Q1 2024 in Review

UBS AM sold out of Ventyx Biosciences (VTYX) in Q1 2024, closing a stake of 77,234 shares — an estimated $191K sold.

UBS AM first reported a position in VTYX in Q4 2022 and held it in 5 quarters. The position peaked at $1.71M in Q3 2023. 126 funds tracked by Wall St. Rank hold VTYX as of Q1 2024.

  • UBS AM reported no remaining Ventyx Biosciences position as of Q1 2024 after selling out during the quarter.
  • UBS AM sold 77,234 Ventyx Biosciences shares in Q1 2024, an estimated $191K.
  • UBS AM first reported a position in Ventyx Biosciences in Q4 2022 and held it in 5 quarters.
  • UBS AM's Ventyx Biosciences position peaked at $1.71M in Q3 2023.
  • 126 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2024.

Based on UBS AM's 13F filing for Q1 2024, filed 15 May 2024.